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Abstract
The use of low lactose formula (LLF) in term and near-term infants in infants with neonatal abstinence syndrome
(NAS) has been increasing recently. However, the clinical evidence of such use is limited. Our aim in this paper was
to systematically review the current literature about the use of LLF in infants with NAS. We searched PubMed,
Embase, Cumulative Index to Nursing and Allied Health Literature, and Cochrane Database of Systematic Reviews
for articles published between 2015 and 2020. Only randomized controlled trials, prospective, and retrospective
studies. The risk of bias was assessed by using published tools appropriate for the study type. The certainty of
the evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation
(GRADE). Forty-one titles and/or abstracts were screened independently by 2 reviewers (MA and GA). After
an indepth review, 4 studies answered the study question (1 randomized controlled trial (RCT), 2 retrospective
studies, and 1 quality improvement study). A meta-analysis could not be completed due to the study type difference
and how the outcomes were reported. The studies found no benefit to feeding LLF to infants with NAS regarding
short-term outcomes (length of stay, duration, and need for pharmacological therapy and growth). Certainty in
the evidence is low. In conclusion we found no beneficial effects regarding the need for pharmacological therapy,
duration of pharmacological treatment, length of hospital stay, and growth of using LLF compared to the standard
formula in infants with NAS.
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Background
Newborns exposed to various opioids and other illicit
substances in utero as part of a treatment program or
addictive behavior are at risk of withdrawal and development of neonatal abstinence syndrome (NAS) due to
discontinuation of exposure after birth. The type and
intensity of withdrawal depend on many factors, including but not limited to the substance used, gestational age
at birth, polysubstance abuse, breastfeeding, and genetic
polymorphisms.1 There has been a national increase
in NAS incidence in the last decade. This incidence
increase has resulted in a significant increase in the
admissions to neonatal intensive care units and pediatric
floors. A study that included 28 states reported a 300%

increase in NAS diagnoses from 1999 to 2013.2 The
care and extended hospital stay for each patient with
NAS can cost the health care system up to $53 400 US
dollars.3 The rise in incidence and the resulting medical
and financial burdens have been substantial driving
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factors for studying this condition’s evaluation and
management.4
Treatment of symptoms associated with NAS is generally based on a combination of pharmacological and
non-pharmacological measures. Multiple pharmacological treatment protocols are followed by using morphine,
methadone, or other medications.1 However, starting
medications for NAS treatment significantly increases
the length of stay (LOS).5 For that reason, infants with
mild to moderate NAS are most often managed with
non-pharmacological measures, and most practices try
to avoid pharmacological therapy. Research has recently
focused on non-pharmacological factors, such as
withdrawal scoring systems, rooming in with mother,
minimizing surrounding environmental noise, nutritional
management, gentle handling, on-demand feeding,
swaddling, music and massage therapy, and skin-toskin care with caregivers.1,6
The literature has clearly shown that maternal breastmilk is beneficial for infants with NAS and significantly
decreases the need for pharmacological therapy and the
LOS.6 However, the evidence is less clear regarding the
type of formula to be used if maternal breastmilk is
unavailable or contraindicated. Given gastrointestinal
(GI) system involvement of NAS, a recent trend has been
observed of using low lactose formula (LLF) in infants
with NAS.7,8 The non-evidence-supported use of these
formulas is based on the hypothesis that partially hydrolyzed protein and low/free lactose carbohydrate decrease
feeding intolerance and fussiness associated with NAS.

Methods
In this systematic review, we aimed to understand
whether the use of LLF decreases the severity and the
duration of NAS symptoms among term and near-term
infants (≥35 weeks of gestation) with NAS compared
with infants who received regular standard formula
(RSF).

Inclusion Criteria
Studies that were eligible for inclusion included those
that investigated the effect of using LLF in term or nearterm infants with NAS diagnaosis. In the included studies, the authors compared the outcomes regarding the
need for pharmacological therapy for NAS, duration or
cumulative dose of pharmacological treatment, length of
hospital stay, and effect on growth between the infants
who received LLF and those who used RSF. Randomized
controlled trials (RCTs), cohort, case-control observational, and quality improvement studies were included in
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the search. Case reports and case series were excluded.
All written languages were accepted if an English
abstract was provided.

Outcomes
The 4 outcomes analyzed in this systematic review
included the need for pharmacological treatment, pharmacological treatment duration, length of hospitalization, and effect on growth if studied.

Literature Search
A medical librarian (KS) performed the search on
December 22, 2020, of the available databases (PubMed,
Embase, Cumulative Index to Nursing and Allied Health
Literature, Cochrane Database of Systematic Reviews).
A search method was performed from the year 2015 to
2020 utilizing the use of keywords and headings
((“Neonatal Abstinence Syndrome/diet therapy”) OR
((“Neonatal Abstinence Syndrome” OR “neonatal abstinence syndrome”) AND (“Infant Formula” OR “Enteral
Nutrition” OR low lactose formula OR lactose-free formula OR protein partially hydrolyzed formula OR formula OR formula OR Feeds OR Feeding OR Enteral)))
from the year of 2015 to 2020.

Study Selection and Extraction
Titles and abstracts were independently screened by 2
authors, MA and GA, who screened the full-text articles.
Discrepancies were discussed and resolved after agreement with all investigators.

The Certainty of the Evidence,
Risk of Bias Assessment, and Data
Synthesis
GRADE was used to assess the overall certainty of the
evidence.9 The Cochrane Collaboration Risk of Bias
Tool was used to evaluate the RCT.10 A meta-analysis
could not be completed due to the difference in the study
type and statistical heterogeneity of the outcomes.

Results
Study Selection
Among 41 articles selected, 4 met the inclusion criteria:
2 cohort studies, 1 randomized controlled trial, and 1
quality improvement study, Figure 1.11-14 The inclusion of 1 other study was ruled out after discussion and
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Figure 1. Prisma flow chart.

agreement between the authors.15 Study types, methodology, and limitations are shown in Table 1.
The 4 studies were from different institutions. The
studies used 3-arm comparisons between LLF, RSF, and
human milk. For this review’s specific aim, we focused
mainly on whether using LLF was more beneficial
regarding short-term outcomes in infants with NAS.
Alsaleem et al11 and Pandey et al14 reported the type of
LLF (Similac Sensitive (Abbott, Columbus, OH), and/or
Enfamil Gentlease (Mead Johnson & Co., Glenview,
IL)) that was used in the analysis. The other 2 studies did
not specifically mention the kind of LLF used in the
study population.12,13
Morphine was the most common pharmacological
therapy used in the studies included.11,12,14 Lembeck
et al13 did not specifically mention which medication
was used for treatment. The quality improvement project reported the use of morphine in most intensive care
units, with a small number of newborns treated with
methadone.12 The pharmacological therapy needs
assessment was based on either the pharmacological
therapy duration or the cumulative dose of morphine

administered during the treatment duration. The risk of
bias analysis for the RCT is shown in Table 2.

Results by Outcomes
Duration of pharmacological therapy. Three studies
(Alsaleem et al, 2020; Lembeck et al, 2020; Pandey
et al, 2020) measured the duration of treatment in infants
with NAS (N = 428). Alsaleem et al measured the duration of morphine sulfate (MSO4) treatment in infants fed
LLF versus RSF (n = 110). After adjusting for the type
of drug used by the mother, regular maternal involvement in prenatal care, maternal smoking status, and
maximum scores prior to MSO4 treatment, the intervention (LLF) was not different from RSF.11 Lembeck
et al13 measured the duration of therapy in infants fed
LLF versus RSF (n = 129). The authors found that the
intervention (LLF) was not different from RSF. Pandey
et al measured medication treatment duration in infants
fed LLF versus infants fed RSF (n = 69). The mean difference of treatment duration in days indicated the intervention (LLF) was not different from RSF.14

4

Gentlease or similac sensitive
1. Selection bias (Cohort)

RSF
1. Need for pharmacological
treatment
2. Duration of pharmacotherapy
3. First day of morphine
treatment
4. Requirement of additional
medication other than
morphine
5. Length of hospital stay
Morphine

Cohort
NAS neonates ≥36 weeks
1. Infants <36 weeks
2. Presence of significant
medical, surgical, or social
condition other than NAS
that could result in prolonged
hospital stay
110

Not reported
1. Selection bias (Cohort)
2. Did not account for all
factors that drive LOS,
treatment failure, or
weight loss
3. Compliance issues

Morphine or methadone

RSF
1. Need for pharmacological
treatment
2. Length of hospital stay
3. Treatment failure
4. Weight loss (>10% within
the first 7 days of life)

546

Quality improvement
NAS neonates >37 weeks
1. Exclusively breastfed
infants

Kaplan et al12

Not reported
1. Selection bias (Cohort)
2. Only 63% of infants
were exclusively fed 1
nutritional source

Not reported

RSF
1. Need for pharmacological
treatment
2. First day of morphine
treatment
3. Length of hospital stay
4. Severity of symptoms
5. Growth

249

Cohort
Neonates >35 weeks
1. Neonates with NAS who
were admitted to the
NICU

Lembeck et al13

Pandey et al14

Similac sensitive
1. Study center changed NAS
treatment guidelines midway
through the study. Criteria for
initiating pharmacologic therapy
were made less stringent to
allow initiation sooner based on
NAS scores. This would likely
affect both groups equally but
remains noteworthy.

Morphine

RSF
1. The cumulative dose of
morphine during the first 14 days
of life
2. Need of additional medication
other than morphine
3. Duration of pharmacological
treatment

69

RCT
Neonates >36 weeks
1. Neonates with significant
congenital anomalies or those
with surgical and medical
conditions that required the use
of analgesics

Abbreviations: NAS, neonatal abstinence syndrome; LOS, length of stay; RSF, regular standard formula; LLF, low lactose formula; NICU, neonatal intensive care unit.

Pharmacological agent
used for treatment
LLF used
Limitations

Number of infants
included
Controls
Outcomes reported

Study design
Subjects
Exclusion criteria

Alsaleem et al11

Table 1. Summary of the Type and Methodology of Included Studies.
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Table 2. Risk of Bias Analysis for RCT Performed by Pandey et al14.
Risk of bias
Bias

Scholar’s judgment

Random sequence
generation (selection bias)

Low risk

Allocation concealment
(selection bias)
Blinding of participants and
personnel (performance
bias)

Low risk

Blinding of outcome
assessment (detection bias)
Incomplete outcome data
(attrition bias)

Low risk

Selective reporting
(reporting bias)
Other bias

Low risk

Low risk

Unclear risk

Low risk

Support for judgment
The randomization was done using a computer-generated random
sequence (by research statistician DMS) (1:1) coupled with
the stratified balanced blocked methodology. Stratification
was done based on gender (male/female), gestational
age (≤38 weeks/>38 weeks), and intrauterine exposure
(polysubstance vs methadone or buprenorphine only).
Allocation concealment was done using an opaque envelope.
One member of the research team, not involved in clinical
management, knew the group assignment. All other members
of the research and clinical management teams remained
blinded to group assignment throughout the study. Study
formula preparation and masking were performed in a hospitaldesignated milk laboratory outside the normal nursery or
NICU by hospital staff who were not involved in the study
recruitment, study management, or data analysis. The study
formula was sent to the bedside in identical transparent
containers labeled “Study formula A” or “Study formula B.”
Parents, health care providers, and primary investigators were
blinded to the study formula type.
Outcomes were objective.
Data analyzed per protocol. Two patients withdrew from each
group with no explanation from the authors. Withdrawal
unlikely to be related to study intervention.
Pre-specified primary and secondary outcomes were reported as
expected.
No additional sources of bias were noted.

The certainty of the evidence for the duration of treatment.
The certainty of the body of evidence was very low. The
body of evidence was assessed to have a risk of bias,
inconsistency, and imprecision. The risk of bias was
assessed as serious as 2 of the studies (Alsaleem et al11
and Lembeck et al13) were retrospective cohorts, resulting in selection bias. Inconsistency was serious due to
the heterogeneity of formulas used, calorie levels, and
feeding type exclusivity. Imprecision was assessed as
serious due to the low number of events.

Length of Stay
Three studies measured LOS in infants with NAS diagnosis (N = 905).11-13 Alsaleem et al11 measured LOS in
infants fed LLF versus RSF (n = 110). After adjusting for
the type of drug used by the mother, regular maternal
involvement in prenatal care and inborn status, smoking
status, and maximum scores prior to MSO4 treatment,
the intervention (LLF) was not different from RSF.11,13
Lembeck et al13 measured LOS in infants exclusively
fed LLF versus those who were fed RSF. The

intervention (LLF) was not different from RSF. Kaplan
et al measured LOS in infants fed low lactose high
calorie (LL + HC) versus high lactose high calorie
(HL + HC) versus low lactose low calorie (LL + LC)
versus high lactose + low calorie (HL + LC) formula.
The mean days indicated that the intervention (LL + HC)
was less effective compared to HL + HC; however, the
significance was not reported. LOS for LL + HC versus
HL + HC was 16.6 and 14.8 days, respectively.12
The certainty of the evidence for LOS. The certainty of the
body of evidence was very low. The body of evidence
was assessed to have a serious risk of bias, serious
inconsistency, and serious imprecision. The risk of bias
was assessed as serious as 2 of the studies (Alsaleem
et al11 and Lembeck et al13) were retrospective cohorts,
resulting in selection bias. Also, the risk of bias was serious as Kaplan et al’s12 study was a quality improvement
study that did not report significance. Inconsistency was
serious due to the heterogeneity of formulas used, calorie levels, and feeding type exclusivity. Imprecision was
assessed as serious due to the low number of events.
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Need for pharmacological therapy. Three studies (Alsaleem et al,11 Lembeck et al,13 and Pandey et al14) measured the need for pharmacologic treatment in infants
with NAS (N = 428). Pandey et al14 indicated that the
intervention (LLF) was not different compared to
RSF. Cumulative morphine for the first 14 days was
20.7 ± 19.8 and 23 ± 23.5 mg for LLF and RSF, respectively. Alsaleem et al measured the need for pharmacological therapy in infants fed LLF versus standard term
formula (n = 110). After adjusting for the type of drug
used by the mother, regular maternal involvement in
prenatal care, smoking status, and maximum scores
prior to MSO4 treatment, the intervention (LLF) was not
different RSF.11 In Lembeck et al,13 the authors found
that the intervention (LLF) was not different from RSF.
The certainty of the evidence for pharmacological therapy.
The certainty of the body of evidence was very low
based. The body of evidence was assessed to have a serious risk of bias, serious inconsistency, and serious
imprecision. The risk of bias was assessed as serious, as
2 of the studies (Alsaleem et al11 and Lembeck et al13)
were retrospective cohorts, resulting in selection bias.
Inconsistency was serious due to the heterogeneity of
formulas used, calorie levels, and feeding type exclusivity. Imprecision was assessed as serious due to the low
number of events.
Growth. One study (Lembeck et al) measured growth in
infants exclusively fed LLF versus RSF (n = 129). The
authors reported that the intervention (LLF) was not different from RSF.13
The certainty of the evidence for growth. The certainty of
the body of evidence was very low. The body of evidence was assessed to have a serious risk of bias and
serious imprecision. The risk of bias was assessed as
serious, as the study (Lembeck et al) was a retrospective
cohort, resulting in selection bias 13. Imprecision was
considered serious due to the low number of events. As
only 1 study (Lembeck et al13) was identified to assess
the effect of LLF on growth, consistency could not be
assessed. More detailed information and statistical analysis of the included studies’ outcomes are shown in Supplemental Table 1.

Discussion
Our goal was to evaluate the possible short-term beneficial effects of using LLF in term or near-term neonates
with NAS in this review of the current literature. Our
systematic review of 4 studies found no benefit regarding short-term outcomes (the need for pharmacological
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therapy, duration of pharmacological treatment, LOS,
and growth) using LLF compared to RSF in infants with
NAS. Overall, the use of LLF did not improve the outcomes in neonates with NAS.
LLFs are different from RSF by having reduced or
absent lactose content in addition to the presence of partially hydrolyzed protein components. Different brands
are available on the market, such as Similac Sensitive,
Enfamil Gentlease, and Gerber Good Start Gentle.16 The
carbohydrate source in these formulas is usually derived
from corn syrup solids compared to the standard human
or cow milk that is mostly lactose derived. The reduced
amount of lactose in these formulas can potentially
interfere with the normal biological functions in neonates because lactose is an essential energy source in
neonates and plays a role in calcium absorption and
innate immunity.17-20 Another potential drawback of
these formulas is derived from the fact that the partially
digested proteins do not have a similar trophic effect on
the bioactive peptides and enzymes required for the normal digestive function in comparison to intact proteins
present in humans or cows milk.21,22 Studies have shown
that, in addition to the interference with these important
biochemical functions, LLF has a bitter taste due to the
partially hydrolyzed proteins when compared to RSF.23
The LLF is usually an alternative to RSF for infants
who experience feeding intolerance, severe colic symptoms, or reflux episodes. As NAS symptoms involve the
GI system, these formulas have become an attractive
option for infants with NAS to decrease GI symptom
severity. Although evidence of such use lacked before
2019, the increasing trend of using these formulas has
allowed researchers to evaluate this intervention’s
evidence-based practice. We found 2 cohort studies, 1
quality improvement project, and 1 double-controlled
randomized trial performed recently that have shed
light on the use of LLF in infants with NAS. We speculate that the results reported in this review originated
from the pathophysiological mechanism associated with
GI withdrawal symptoms seen in infants with NAS.
Holzer showed that the effects of opioids on the GI tract
are caused primarily by altering the acetylcholine neurotransmitter and receptor interaction. The reduced
amount of lactose or the partially hydrolyzed proteins in
LLF is unlikely to affect the signs and symptoms associated with the disturbance of the acetylcholine neurotransmitter pathway.24
Although assessing the effect of maternal breast milk
(MBM) on NAS outcomes was not the purpose of this
review, we found that the authors of the 4 studies
included in this systematic review found a consistent
beneficial effect of MBM regarding the short-term outcomes (need for pharmacological therapy, duration of
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pharmacological treatment, and hospital LOS). This
observation is consistent with established evidence from
previous studies showing favorable outcomes of infants
with NAS who received human milk.25,26
The strengths of this systematic review include the
detailed literature search and assessment of the certainty
of evidence using GRADE and the detailed analysis of
the specific outcomes targeted in this review. Limitations
include the small number of eligible studies and the significant heterogeneity between the included studies
regarding outcomes reported. The lack of details about
the percentage for the specific formula intake and the
slightly different treatment protocols followed in each of
the studies were additional limiting factors for which we
could not control in this systematic review. Given the
theoretical adverse effects of using LLF that may compromise calcium absorption and digestive function, we
remain concerned about the lack of clear evidence for
the use of LLF in infants with NAS.

Conclusion
From the limited evidence currently available, we did
not find beneficial effects regarding the need for pharmacological therapy, duration of pharmacological treatment, LOS, and growth of using LLF compared to other
standard formulas in infants with NAS. A conditional
recommendation is made against LLF, as no beneficial
effects were found in patients with NAS. This recommendation is based on expert opinion and a review of
the current literature. The overall certainty of the evidence is low.
Acknowledgments
The authors would like to extend a sincere thanks to the following: K. Swaggart, MLIS, AHIP, for performing the literature search. Office of Evidence-based Practice at Children’s
Mercy Hospital for performing the data analysis. Medical
Writing Center at Children’s Mercy Hospital for editing this
manuscript.

Author Contributions
MA: Contributed to design, research, acquisition, analysis,
and interpretation; drafted manuscript; critically revised manuscript; gave final approval; and agrees to be accountable for
all aspects of work ensuring integrity and accuracy.
GA: Contributed to conception, design, analysis, and interpretation; critically revised manuscript; gave final approval; and
agrees to be accountable for all aspects of work, ensuring
integrity and accuracy.
JD: Contributed to analysis and interpretation; critically
revised manuscript; gave final approval; and agrees to be
accountable for all aspects of work, ensuring integrity and
accuracy.

7
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with
respect to the research, authorship, and/or publication of this
article.

Funding
The author(s) received no financial support for the research,
authorship, and/or publication of this article.

ORCID iDs
Mahdi Alsaleem
https://orcid.org/0000-0002-2285-2963
Gangaram Akangire
https://orcid.org/0000-0001-7796
-7672

Supplemental Material
Supplemental material for this article is available online.

References
1. Kocherlakota P. Neonatal abstinence syndrome.
Pediatrics. 2014;134(2):e547-e561.
2. Ko JY, Patrick SW, Tong VT, Patel R, Lind JN, Barfield
WD. Incidence of neonatal abstinence syndrome – 28
states, 1999-2013. MMWR Morb Mortal Wkly Rep.
2016;65(31):799-802.
3. Siu A, Robinson CA. Neonatal abstinence syndrome:
essentials for the practitioner. J Pediatr Pharmacol Ther.
2014;19(3):147-155.
4. Patrick SW, Schumacher RE, Benneyworth BD, Krans
EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United
States, 2000-2009. JAMA. 2012;307(18):1934-1940.
5. Wright TE. Opioid-Use Disorders in Pregnancy: Manage
ment Guidelines for Improving Outcomes. Cambridge
University Press; 2018.
6. Wachman EM, Grossman M, Schiff DM, et al. Quality
improvement initiative to improve inpatient outcomes
for neonatal abstinence syndrome. J Perinatol. 2018;38
(8):1114-1122.
7. Walsh MC, Crowley M, Wexelblatt S, et al. Ohio perinatal
quality collaborative improves care of neonatal narcotic
abstinence syndrome. Pediatrics. 2018;141(4):230-240.
8. Bogen DL, Whalen BL, Kair LR, Vining M, King BA.
Wide variation found in care of opioid-exposed newborns.
Acad Pediatr. 2017;17(4):374-380.
9. Higgins JP, Thomas J, Chandler J, et al. Cochrane
Handbook for Systematic Reviews of Interventions. John
Wiley & Sons; 2019.
10. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an
emerging consensus on rating quality of evidence and
strength of recommendations. Br Med J (Clin Res Ed).
2008;336(7650):924-926.
11. Alsaleem M, Berkelhamer SK, Wilding GE, Miller LM,
Reynolds AM. Effects of partially hydrolyzed formula on
severity and outcomes of neonatal abstinence syndrome.
Am J Perinatol. 2020;37(11):1177-1182.

8
12. Kaplan HC, Kuhnell P, Walsh MC, et al. Orchestrated
testing of formula type to reduce length of stay in neonatal
abstinence syndrome. Pediatrics. 2020;146(4):100-110.
13. Lembeck AL, Tuttle D, Locke R, et al. Breastfeeding and
formula selection in neonatal abstinence syndrome. Am
J Perinatol. 2020. Published online June 30, 2020. doi:
10.1055/s-0040-1713754
14. Pandey R, Kanike N, Ibrahim M, et al. Lactose-free infant
formula does not change outcomes of neonatal abstinence
syndrome (NAS): a randomized clinical trial. J Perinatol.
2021;41(3):598-605.
15. Bogen DL, Hanusa BH, Baker R, Medoff-Cooper B,
Cohlan B. Randomized clinical trial of standard- versus
high-calorie formula for methadone-exposed infants: a
feasibility study. Hosp Pediatr. 2018;8(1):7-14.
16. Belamarich PF, Bochner RE, Racine AD. A critical review
of the marketing claims of infant formula products in the
United States. Clin Pediatr (Phila). 2016;55(5):437-442.
17. Abrams SA, Griffin IJ, Davila PM. Calcium and zinc
absorption from lactose-containing and lactose-free infant
formulas. Am J Clin Nutr. 2002;76(2):442-446.
18. Cederlund A, Kai-Larsen Y, Printz G, et al. Lactose in
human breast milk an inducer of innate immunity with
implications for a role in intestinal homeostasis. PLoS
One. 2013;8(1):e53876.
19. Levenson DI, Bockman RS. A review of calcium preparations. Nutr Rev. 1994;52(7):221-232.

Global Pediatric Health
20. Turco R, Russo M, Bruzzese D, Staiano A. Efficacy of a
partially hydrolysed formula, with reduced lactose content and with Lactobacillus reuteri DSM 17938 in infant
colic: a double blind, randomised clinical trial. Clin Nutr.
2021;40(2):412-419.
21. Vandenplas Y, Alarcon P, Fleischer D, et al. Should
partial hydrolysates be used as starter infant formula? A
working group consensus. J Pediatr Gastroenterol Nutr.
2016;62(1):22-35.
22. Fleischer DM, Venter C, Vandenplas Y. Hydrolyzed
formula for every infant? Protein in neonatal and infant
nutrition: recent updates. Nestlé Nutr Inst Workshop Ser.
2016;86:51-65.
23. Miraglia Del Giudice M, D’Auria E, Peroni D, et al.
Flavor, relative palatability and components of cow’s
milk hydrolysed formulas and amino acid-based formula.
Ital J Pediatr. 2015;41(1):42.
24. Holzer P. Pharmacology of opioids and their effects on
gastrointestinalfunction. Am J Gastroenterol Suppl. 2014;
2(1):9–16.
25. Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J.
Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics. 2006;117(6):e1163-e1169.
26. de Vries L. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of
drug-dependent mothers. Breastfeed Rev. 2007;15(1):39-40.

